WeRide, CRISPR And GeneDx Are Amongst Prime 10 Mid-Cap Gainers Final Week (Feb 10-Feb 14): Are The Others In Your Portfolio? – GeneDx Hldgs (NASDAQ:WGS), CRISPR Therapeutics (NASDAQ:CRSP), WeRide (NASDAQ:WRD)

These ten mid-cap shares have been the perfect performers within the final week. Are they in your portfolio?

1. WeRide Inc. WRD shares rocketed 97.62% after NVIDIA Company NVDA disclosed a stake of 1.74 million shares in a 13F submitting.
2. GDS Holdings Restricted GDS inventory escalated 43.45%, in all probability after President Trump had reportedly postponed tariffs on packages below $800 from China. Moreover, optimism in direction of China’s DeepSeek AI mannequin has additionally lifted shares not too long ago.
3. SpringWorks Therapeutics, Inc. SWTX shares jumped 42.58% after asserting Merck KGaA MKGAF MKKGY is in superior discussions to accumulate the corporate.
4. Recursion Prescribed drugs, Inc. RXRX shares elevated 40.59%.
5. Sable Offshore Corp. SOC inventory upped 39.09%.
6. GeneDx Holdings Corp. WGS shares rose 28.23%  after the corporate introduced UltraRapid Complete Genome Sequencing, which can ship actionable outcomes inside 48 hours.
7. VNET Group, Inc. VNET inventory upped 28.22%, in all probability amid a attainable rebound after falling final week as a consequence of AI competitors considerations associated to China’s DeepSeek AI mannequin.
8. Insperity, Inc. NSP inventory elevated 25.99% after the corporate reported better-than-anticipated fourth-quarter outcomes.
9. CRISPR Therapeutics AG CRSP inventory grew 25.21% after the corporate reported better-than-anticipated fourth-quarter monetary outcomes. A number of analysts raised the worth forecast on the inventory.
10. Axsome Therapeutics, Inc. AXSM inventory grew 24.01% after the corporate reached a settlement settlement with Teva Pharmaceutical TEVA, resolving all patent litigation associated to its Auvelity product. A number of analysts raised the worth forecast on the inventory.

Picture by way of WeRide